252 related articles for article (PubMed ID: 1698909)
1. Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.
Voss SD; Robb RJ; Weil-Hillman G; Hank JA; Sugamura K; Tsudo M; Sondel PM
J Exp Med; 1990 Oct; 172(4):1101-14. PubMed ID: 1698909
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R.
Voss SD; Sondel PM; Robb RJ
J Exp Med; 1992 Aug; 176(2):531-41. PubMed ID: 1500859
[TBL] [Abstract][Full Text] [Related]
3. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.
Carson WE; Giri JG; Lindemann MJ; Linett ML; Ahdieh M; Paxton R; Anderson D; Eisenmann J; Grabstein K; Caligiuri MA
J Exp Med; 1994 Oct; 180(4):1395-403. PubMed ID: 7523571
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of KOLT-2 antigen (CD28) by interleukin 2; role of IL-2R (p70).
Shindo T; Sugie K; Nakamura K; Tagaya Y; Maeda M; Uchiyama T; Sagawa K; Yokoyama M; Wada H; Hitomi S
Immunology; 1990 Sep; 71(1):63-9. PubMed ID: 2170270
[TBL] [Abstract][Full Text] [Related]
5. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells.
Baume DM; Robertson MJ; Levine H; Manley TJ; Schow PW; Ritz J
Eur J Immunol; 1992 Jan; 22(1):1-6. PubMed ID: 1370410
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of the interleukin 2 receptor beta (p75) chain on human peripheral blood natural killer subsets.
Nishikawa K; Saito S; Morii T; Kato Y; Narita N; Ichijo M; Ohashi Y; Takeshita T; Sugamura K
Int Immunol; 1990; 2(6):481-6. PubMed ID: 1707657
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of CD16-CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua.
Nishikawa K; Saito S; Morii T; Hamada K; Ako H; Narita N; Ichijo M; Kurahayashi M; Sugamura K
Int Immunol; 1991 Aug; 3(8):743-50. PubMed ID: 1716974
[TBL] [Abstract][Full Text] [Related]
8. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
Bayle C; Vitté-Mony I; Lang P; Pico J; Hercend T; Bertoglio J
Leukemia; 1992 May; 6(5):470-6. PubMed ID: 1375700
[TBL] [Abstract][Full Text] [Related]
9. Regulation of CD3- lymphocyte function with an antibody against the IL-2 beta chain receptor: modulation of NK and LAK activity and production of IFN gamma.
Ortaldo JR; Frey J; Takeshita T; Sugamura K
Eur Cytokine Netw; 1990; 1(1):27-34. PubMed ID: 2151685
[TBL] [Abstract][Full Text] [Related]
10. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
Levitt LJ; Nagler A; Lee F; Abrams J; Shatsky M; Thompson D
J Clin Invest; 1991 Jul; 88(1):67-75. PubMed ID: 1676038
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.
Naume B; Gately M; Espevik T
J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169
[TBL] [Abstract][Full Text] [Related]
12. Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells.
Kehrl JH; Dukovich M; Whalen G; Katz P; Fauci AS; Greene WC
J Clin Invest; 1988 Jan; 81(1):200-5. PubMed ID: 2826541
[TBL] [Abstract][Full Text] [Related]
13. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.
Weil-Hillman G; Voss SD; Fisch P; Schell K; Hank JA; Sosman JA; Sugamura K; Sondel PM
Cancer Res; 1990 May; 50(9):2683-91. PubMed ID: 1691679
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells.
Nakarai T; Robertson MJ; Streuli M; Wu Z; Ciardelli TL; Smith KA; Ritz J
J Exp Med; 1994 Jul; 180(1):241-51. PubMed ID: 8006584
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric analysis of expression of interleukin-2 receptor beta chain (p70-75) on various leukemic cells.
Hoshino S; Oshimi K; Tsudo M; Miyasaka M; Teramura M; Masuda M; Motoji T; Mizoguchi H
Blood; 1990 Aug; 76(4):767-74. PubMed ID: 2383656
[TBL] [Abstract][Full Text] [Related]
17. Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ.
Weidmann E; Sacchi M; Plaisance S; Heo DS; Yasumura S; Lin WC; Johnson JT; Herberman RB; Azzarone B; Whiteside TL
Cancer Res; 1992 Nov; 52(21):5963-70. PubMed ID: 1394222
[TBL] [Abstract][Full Text] [Related]
18. IL-2 receptors on circulating natural killer cells and T lymphocytes. Similarity in number and affinity but difference in transmission of the proliferation signal.
Ben Aribia MH; Moiré N; Métivier D; Vaquero C; Lantz O; Olive D; Charpentier B; Senik A
J Immunol; 1989 Jan; 142(2):490-9. PubMed ID: 2783438
[TBL] [Abstract][Full Text] [Related]
19. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors.
Caligiuri MA; Zmuidzinas A; Manley TJ; Levine H; Smith KA; Ritz J
J Exp Med; 1990 May; 171(5):1509-26. PubMed ID: 1692080
[TBL] [Abstract][Full Text] [Related]
20. Expression of low-, intermediate-, and high-affinity IL-2 receptors on B cell lines derived from patients with undifferentiated lymphoma of Burkitt's and non-Burkitt's types.
Benjamin D; Rosolen A; Wormsley SB; DeBault LE; Colamonici OR
Cell Immunol; 1990 Aug; 129(1):112-24. PubMed ID: 2364438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
